Assessing Amicus Therapeutics (FOLD) Valuation After Recent Share Price Momentum [Yahoo! Finance]
Is Amicus Therapeutics (FOLD) Pricing Reflect Recent 45% Surge And DCF Upside Potential [Yahoo! Finance]
Halper Sadeh LLC Encourages THS, FOLD, REVG Shareholders to Contact the Firm to Discuss Their Rights
Amicus Therapeutics (NASDAQ:FOLD) was downgraded by analysts at Guggenheim from a "strong-buy" rating to a "hold" rating.
Amicus Therapeutics (NASDAQ:FOLD) was downgraded by analysts at Leerink Partners from an "outperform" rating to a "market perform" rating. They now have a $14.50 price target on the stock.